Sugi Predict

Sugi Predict / Compounds / SCHEMBL677390

SCHEMBL677390

SCHEMBL677390

CCN(CC)C(=O)Cc1csc(NS(=O)(=O)c2cccc(Cl)c2C)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ HSD11B1 P28845 7/20 1.00
▸ HSD17B1 P14061 2/20 1.00
▸ HSD17B2 P37059 2/20 1.00
▸ KMT2A Q03164 6/20 0.55
▸ MEN1 O00255 5/20 0.55
▸ POLB P06746 1/20 0.55
▸ ALDH1A1 P00352 3/20 0.50
▸ CYP2C9 P11712 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ CTPS1 P17812 2/20 0.46
▸ PKM P14618 2/20 0.46
▸ LMNA P02545 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3619776 0.92 HSD11B1 (0.85) HSD11B1HSD17B1HSD17B2KMT2AMEN1
SCHEMBL3616949 0.92 HSD11B1 (0.84) HSD11B1HSD17B1HSD17B2KMT2AMEN1
SCHEMBL3621302 0.91 HSD11B1 (0.84) HSD11B1HSD17B1HSD17B2KMT2AMEN1
SCHEMBL3614677 0.90 HSD11B1 (0.81) HSD11B1HSD17B1HSD17B2KMT2AMEN1
SCHEMBL3621755 0.88 HSD11B1 (0.79) HSD11B1HSD17B1HSD17B2KMT2AMEN1
SCHEMBL3611985 0.87 HSD11B1 (0.77) HSD11B1HSD17B1HSD17B2KMT2AMEN1
SCHEMBL13171476 0.87 HSD11B1 (0.77) HSD11B1HSD17B1HSD17B2KMT2AMEN1
SCHEMBL3614035 0.87 HSD11B1 (0.77) HSD11B1HSD17B1HSD17B2KMT2AMEN1
SCHEMBL3612714 0.86 HSD11B1 (0.76) HSD11B1HSD17B1HSD17B2KMT2AMEN1
SCHEMBL3611692 0.86 HSD11B1 (0.76) HSD11B1HSD17B1HSD17B2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 BIOVITRUM AB 2010-05-06 — — US claimed
US-7618961-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2009-11-17 — — US claimed
EP-1638553-A1 NEW USE I BIOVITRUM AB (SE) 2006-03-29 — — EP claimed
US-20050137209-A1 Treatment of neurologic disorders with inhibitors of 11beta-HSD1 AGY THERAPEUTICS, INC. 2005-06-23 — — US claimed
WO-2004112784-A1 NEW USE I BIOVITRUM AB (SE) 2004-12-29 — — WO claimed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 — — US claimed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 — — EP claimed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 — — WO claimed
WO-2025068686-A1 TREATMENT FOR BATTEN DISEASE THE ROYAL VETERINARY COLLEGE (GB) 2025-04-03 — — WO disclosed
US-11590119-B2 (S)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid for use in medicine UNIVERSITY OF LEEDS (GB) 2023-02-28 — — US disclosed
EP-4058022-A1 (S)-2-(1-(5-(CYCLOHEXYLCARBAMOYL)-6-(PROPYLTHIO)PYRIDIN-2-YL)PIPERIDIN-3-YL) ACETIC ACID FOR USE IN TREATING WOUNDS University of Leeds (GB) 2022-09-21 — — EP disclosed
CN-111743898-A Application of 11 beta-HSD 1inhibitor in protecting neural stem cells in stress environment 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 2020-10-09 — — CN disclosed
US-10039772-B2 Methods and compositions for treating alcohol use disorders SANNA PIETRO PAOLO (US) 2018-08-07 — — US disclosed
US-10039772-B2 Methods and compositions for treating alcohol use disorders SANNA PIETRO PAOLO (US) 2018-08-07 — — US disclosed
EP-1638553-A1 NEW USE I BIOVITRUM AB (SE) 2006-03-29 — — EP disclosed
US-20050137209-A1 Treatment of neurologic disorders with inhibitors of 11beta-HSD1 AGY THERAPEUTICS, INC. 2005-06-23 — — US disclosed
WO-2004112784-A1 NEW USE I BIOVITRUM AB (SE) 2004-12-29 — — WO disclosed
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2004-11-11 — — US disclosed
EP-1283831-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-02-19 — — EP disclosed
WO-2001090090-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2001-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11590119-B2 (S)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl)acetic acid for use in medicine STK17A, IL17A, MAPK15 HSD11B1 2864/4885HSD17B1 1166/4885HSD17B2 1726/4885
US-10039772-B2 Methods and compositions for treating alcohol use disorders HSD3B1, HSD11B1, HSD3B2 HSD11B1 2/4885HSD17B1 5/4885HSD17B2 6/4885
US-20050137209-A1 Treatment of neurologic disorders with inhibitors of 11beta-HSD1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 7/4885
US-20040224996-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885
US-20100113435-A1 INHIBITORS OF 11-BETA-HYDROXY STERIOD DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD3B1 HSD11B1 1/4885HSD17B1 2/4885HSD17B2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.